A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis

2017273 citationsJournal Articlehybrid Open Access

Authors

Kris V. Kowdley · Swedish Medical Center

Velimir A. Luketic · Virginia Commonwealth University

Roger W. Chapman · John Radcliffe Hospital

Gideon M. Hirschfield · University of Birmingham

Raoul Poupon · Hôpital Saint-Antoine

Christoph Schramm · Universität Hamburg

Catherine Vincent

Abstract

OCA monotherapy significantly improved alkaline phosphatase and other biochemical markers predictive of improved long-term clinical outcomes. Pruritus increased dose-dependently with OCA treatment. Biochemical improvements were observed through 6 years of open-label extension treatment. (Hepatology 2018;67:1890-1902).

Topics & Keywords

Liver Diseases and Immunity Drug Transport and Resistance Mechanisms Pediatric Hepatobiliary Diseases and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Hepatology

Volume 67, Issue 5, pp. 1890-1902

DOI: 10.1002/hep.29569

Field-Weighted Citation Impact: 14.44